Physician profile
John Patterson
NPI 1568653269
$10,138.97
in general payments reported to CMS, 2019-2025
54 companies · $887 in 2025
The $887 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $918 · 2021: $2,311 · 2022: $1,577 · 2023: $1,569 · 2024: $1,493 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Long Term Medical Supply Or Device Loan: $29.97 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.78 |
| Long Term Medical Supply Or Device Loan | $29.97 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,334.71 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $1,196.42 | 2020-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $932.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $734.71 | 2019-2025 | Jardiance |
| Amgen INC. | $533.28 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $508.78 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.33 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $405.76 | 2019-2024 | Spravato, Xarelto |
| Nestle Healthcare Nutrition INC. | $321.86 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $306.30 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $303.77 | 2019-2021 | |
| Stryker Corporation | $299.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $228.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $217.88 | 2019-2025 | Airsupra |
| Ucb, INC. | $207.10 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.